1 Survey summary PTCL clinical practice recommendations
2 Q1 - What is your age? # Answer % Count 1 30-39 years 3.23% 241.94% 13 3 50-59 years 38.71% 12 4 60-69 years 12.90% 5 70+ years Total 100% 31
3 Q2 - How many years have you been inpractice since completing your specialty training? # Answer % Count 1 < 5 years 0.00% 2 5-9 years 9.68% 3 10-19 years 48.39% 15 4 20-29 years 29.03% 9 5 30+ years 12.90% Total 100% 31
4 Q3 - Do you consider yourself# Answer % Count 1 A transplant physician (defined as spending >75% of your time in the care of patients undergoing autologous or allogeneic HCT) 25.81% 8 2 A hematologist, Oncologist, or hematologist-Oncologist (defined as spending >75% of your time in the care of patients in a non-transplant setting) 35.48% 11 3 A mixed practice (50% transplant and 50% non-transplant practice) 38.71% 12 Total 100% 31
5 Q4 - To the best of your knowledge, how manyautologous HCT does your center perform every year (all diseases)? # Answer % Count 1 < 50 9.68% 3 2 50-99 29.03% 9 16.13% 5 4 200+ 35.48% 11 Total 100% 31
6 Q5 - To the best of your knowledge, howmany allogeneic HCT does your center perform every year (all diseases)? # Answer % Count 1 < 50 13.33% 4 2 50-99 23.33% 7 3 20.00% 6 16.67% 5 200+ 26.67% 8 Total 100% 30
7 Q7 - Peripheral T-cell lymphoma, NOSIs there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 96.67% 29 2 No 3.33% Total 100% 30
8 Q8 - Peripheral T-cell lymphoma, NOSDoes the IPI-score at diagnosis influence your decision to consider (or not) high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 50.00% 15 2 No Total 100% 30
9 Q9 - Peripheral T-cell lymphoma, NOSDoes the PIT-score at diagnosis influence your decision to consider (or not) high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 44.83% 13 2 No 55.17% 16 Total 100% 29
10 Q10 - Peripheral T-cell lymphoma, NOSDoes presence of bone marrow involvement with disease at diagnosis influence your choice of transplant modality? # Answer % Count 1 Yes, favors allogeneic HCT 46.43% 13 2 No, autologous HCT remains an acceptable modality 53.57% 15 Total 100% 28
11 Q11 - Peripheral T-cell lymphoma, NOSIs there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 64.00% 16 2 No 36.00% 9 Total 100% 25
12 Q12 - Peripheral T-cell lymphoma, NOSDoes the IPI-score at diagnosis influence your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 25.93% 7 2 No 74.07% 20 Total 100% 27
13 Q13 - Peripheral T-cell lymphoma, NOSDoes the PIT-score at diagnosis influence your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 22.22% 6 2 No 77.78% 21 Total 100% 27
14 Q14 - Peripheral T-cell lymphoma, NOSIs there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes (only if autologous HCT not done in front-line consolidation) 88.89% 24 5 Yes (even if autologous HCT done in front-line consolidation) 0.00% 2 No 11.11% 3 Total 100% 27
15 Q15 - Peripheral T-cell lymphoma, NOSIs there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes (even if autologous HCT done in front-line consolidation) 100.00% 30 2 No 0.00% Total 100%
16 Q16 - Peripheral T-cell lymphoma, NOSIs there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 16.67% 5 2 No 83.33% 25 Total 100% 30
17 Q17 - Peripheral T-cell lymphoma, NOSIs there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 74.07% 20 2 No 25.93% 7 Total 100% 27
18 Q19 - Angioimmunoblastic T-cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 88.00% 22 2 No 12.00% 3 Total 100% 25
19 Q20 – Angioimmunoblastic T-cell lymphomaDoes the IPI-score at diagnosis influence your decision to consider (or not) high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 38.46% 10 2 No 61.54% 16 Total 100% 26
20 Q21 –Angioimmunoblastic T-cell lymphomaDoes presence of bone marrow involvement at diagnosis influence your choice of transplant modality? # Answer % Count 1 Yes, favor allogeneic HCT 41.67% 10 2 No, autologous HCT remains an acceptable modality 58.33% 14 Total 100% 24
21 Q22 - Angioimmunoblastic T-cell lymphomaIs there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 36.36% 8 2 No 63.64% 14 Total 100% 22
22 Q23 - Angioimmunoblastic T-cell lymphomaDoes the IPI-score at diagnosis influence your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 30.43% 7 2 No 69.57% 16 Total 100% 23
23 Q24 - Angioimmunoblastic T-cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes (only if autologous HCT not done in front-line consolidation) 84.62% 22 5 Yes (even if autologous HCT done in front-line consolidation) 3.85% 2 No 11.54% 3 Total 100% 26
24 Q25 - Angioimmunoblastic T-cell lymphomaIs there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes (even if autologous HCT done in front-line consolidation) 96.30% 26 2 No 3.70% Total 100% 27
25 Q26 - Angioimmunoblastic T-cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 15.38% 4 2 No 84.62% 22 Total 100% 26
26 Q27 - Angioimmunoblastic T-cell lymphomaIs there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 79.17% 19 2 No 20.83% 5 Total 100% 24
27 Q29 -Anaplastic large-cell lymphoma, ALK+Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 24.00% 6 2 No 76.00% 19 Total 100% 25
28 Q30 - Anaplastic large-cell lymphoma, ALK+Does the IPI-score at diagnosis influence your decision to consider (or not) high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 30.43% 7 2 No 69.57% 16 Total 100% 23
29 Q31 - Anaplastic large-cell lymphoma, ALK+Does presence of bone marrow involvement at diagnosis influence your choice of transplant modality? # Answer % Count 1 Yes, favor allogeneic HCT 25.00% 4 2 No, autologous HCT remains an acceptable modality 75.00% 12 Total 100% 16
30 Q32 - Anaplastic large-cell lymphoma, ALK+Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 4.00% 2 No 96.00% 24 Total 100% 25
31 Q33 - Anaplastic large-cell lymphoma, ALK+Does the IPI-score at diagnosis influence your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 4.55% 2 No 95.45% 21 Total 100% 22
32 Q34 - Anaplastic large-cell lymphoma, ALK+Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes (only if autologous HCT not done in front-line consolidation) 100.00% 26 5 Yes (even if autologous HCT done in front-line consolidation) 0.00% 2 No Total 100%
33 Q35 - Anaplastic large-cell lymphoma, ALK+Is there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes (even if autologous done in front-line consolidation) 83.33% 20 2 No 16.67% 4 Total 100% 24
34 Q36 - Anaplastic large-cell lymphoma, ALK+Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 20.83% 5 2 No 79.17% 19 Total 100% 24
35 Q37 - Anaplastic large-cell lymphoma, ALK+Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 70.83% 17 2 No 29.17% 7 Total 100% 24
36 Q39 - Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 92.00% 23 2 No 8.00% Total 100% 25
37 Q41 - Anaplastic large-cell lymphoma, ALK- (negative)Does presence of bone marrow involvement at diagnosis influence your choice of transplant modality? # Answer % Count 1 Yes, favor allogeneic HCT 33.33% 8 2 No, autologous HCT remains an acceptable modality 66.67% 16 Total 100% 24
38 Q40 - Anaplastic large-cell lymphoma, ALK- (negative)Does the IPI-score at diagnosis influence your decision to consider (or not) high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 38.46% 10 2 No 61.54% 16 Total 100% 26
39 Q42 - Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 29.17% 7 2 No 70.83% 17 Total 100% 24
40 Q43 - Anaplastic large-cell lymphoma, ALK- (negative)Does the IPI-score at diagnosis influence your decision to consider (or not) allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 29.17% 7 2 No 70.83% 17 Total 100% 24
41 Q44 - Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes (only if autologous HCT not done in front-line consolidation) 88.89% 24 5 Yes (even if autologous HCT done in front-line consolidation) 0.00% 2 No 11.11% 3 Total 100% 27
42 Q45 - Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes (even if autologous HCT done in front-line consolidation) 96.30% 26 2 No 3.70% Total 100% 27
43 Q46 -Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for high-dose chemotherapy and autologous HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 23.08% 6 2 No 76.92% 20 Total 100% 26
44 Q47 -Anaplastic large-cell lymphoma, ALK- (negative)Is there a role for allogeneic HCT in treatment of refractory disease (primary refractory or refractory relapse)? # Answer % Count 1 Yes 82.61% 19 2 No 17.39% 4 Total 100% 23
45 Q49 -Extranodal NK/T-cell lymphoma nasal typeLocalized Front-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 24.00% 6 2 No 76.00% 19 Total 100% 25
46 Q50 - Extranodal NK/T-cell lymphoma nasal typeLocalized Front-line: Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 17.39% 4 2 No 82.61% 19 Total 100% 23
47 Q51 - Extranodal NK/T-cell lymphoma nasal typeLocalized Is there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes 82.61% 19 2 No 17.39% 4 Total 100% 23
48 Q52 -Extranodal NK/T-cell lymphoma nasal typeLocalized Is there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes 91.67% 22 2 No 8.33% Total 100% 24
49 Q53 - Extranodal NK/T-cell lymphoma nasal typeLocalized Is there a role for high-dose chemotherapy and autologous HCT in treatment of Chemoresistant/refractory disease? # Answer % Count 1 Yes 25.00% 6 2 No 75.00% 18 Total 100% 24
50 Q54 - Extranodal NK/T-cell lymphoma nasal typeLocalized Is there a role for allogeneic HCT in treatment of Chemoresistant/refractory disease? # Answer % Count 1 Yes 81.82% 18 2 No 18.18% 4 Total 100% 22
51 Q56 –Extranodal NK/T-cell lymphoma nasal typeDisseminated Front-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation in disseminated disease (i.e. CR1 or PR1)? # Answer % Count 1 Yes 79.17% 19 2 No 20.83% 5 Total 100% 24
52 Q57 - Extranodal NK/T-cell lymphoma nasal typeDisseminated Front-line: Is there a role for allogeneic HCT in front-line consolidation in disseminated disease (i.e. CR1 or PR1)? # Answer % Count 1 Yes 86.96% 20 2 No 13.04% 3 Total 100% 23
53 Q58 - Extranodal NK/T-cell lymphoma nasal typeDisseminated Is there a role for high-dose chemotherapy and autologous HCT in treatment of disseminated chemosensitive relapsed disease? # Answer % Count 1 Yes 70.83% 17 2 No 29.17% 7 Total 100% 24
54 Q59 - Extranodal NK/T-cell lymphoma nasal typeDisseminated Is there a role for allogeneic HCT in treatment of disseminated chemosensitive relapsed disease? # Answer % Count 1 Yes 100.00% 24 2 No 0.00% Total 100%
55 Q60 - Extranodal NK/T-cell lymphoma nasal typeDisseminated Is there a role for high-dose chemotherapy and autologous HCT in treatment of Chemoresistant/refractory disease? # Answer % Count 1 Yes 20.83% 5 2 No 79.17% 19 Total 100% 24
56 Q61 -Extranodal NK/T-cell lymphoma nasal typeDisseminated Is there a role for allogeneic HCT in treatment of Chemoresistant/refractory disease? # Answer % Count 1 Yes 72.73% 16 2 No 27.27% 6 Total 100% 22
57 Q63 – Adult T-cell Leukemia/LymphomaAcute: Front-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 23.81% 5 2 No 76.19% 16 Total 100% 21
58 Q64 - Adult T-cell Leukemia/LymphomaAcute: Front-line: Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 90.91% 20 2 No 9.09% Total 100% 22
59 Q65 – Adult T-cell Leukemia/LymphomaAcute: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed responsive disease? # Answer % Count 1 Yes 13.64% 3 2 No 86.36% 19 Total 100% 22
60 Acute: Q66 - Adult T-cell Leukemia/LymphomaIs there a role for allogeneic HCT in relapsed responsive disease? # Answer % Count 1 Yes 100.00% 21 2 No 0.00% Total 100%
61 Q67 - Adult T-cell Leukemia/LymphomaAcute: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed resistant disease/refractory disease? # Answer % Count 1 Yes 8.70% 2 No 91.30% 21 Total 100% 23
62 Q68 - Adult T-cell Leukemia/LymphomaAcute: Is there a role for allogeneic HCT in treatment of relapsed resistant disease/refractory disease? # Answer % Count 1 Yes 73.68% 14 2 No 26.32% 5 Total 100% 19
63 Q70 - Adult T-cell Leukemia/LymphomaLymphoma type: Front-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 31.25% 5 2 No 68.75% 11 Total 100% 16
64 Q71 - Adult T-cell Leukemia/LymphomaLymphoma type: Front-line: Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 70.00% 14 2 No 30.00% 6 Total 100% 20
65 Q72 -Adult T-cell Leukemia/LymphomaLymphoma type: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed sensitive disease? # Answer % Count 1 Yes 30.00% 6 2 No 70.00% 14 Total 100% 20
66 Lymphoma type: Q73 - Adult T-cell Leukemia/LymphomaIs there a role for allogeneic HCT in relapsed sensitive disease? # Answer % Count 1 Yes 100.00% 21 2 No 0.00% Total 100%
67 Q74 - Adult T-cell Leukemia/LymphomaLymphoma type: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed resistant disease/refractory disease? # Answer % Count 1 Yes 4.55% 2 No 95.45% 21 Total 100% 22
68 Q75 -Adult T-cell Leukemia/LymphomaLymphoma type: Is there a role for allogeneic HCT in treatment of relapsed resistant disease/refractory disease? # Answer % Count 1 Yes 83.33% 15 2 No 16.67% 3 Total 100% 18
69 Q77 - Adult T-cell Leukemia/LymphomaSmoldering/chronic: Front-line Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 10.53% 2 No 89.47% 17 Total 100% 19
70 Q78 - Adult T-cell Leukemia/LymphomaSmoldering/chronic: Front-line Is there a role for allogeneic HCT in front-line consolidation (i.e. CR1 or PR1)? # Answer % Count 1 Yes 20.00% 4 2 No 80.00% 16 Total 100% 20
71 Q79 -Adult T-cell Leukemia/LymphomaSmoldering/chronic: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapse sensitive disease? # Answer % Count 1 Yes 27.78% 5 2 No 72.22% 13 Total 100% 18
72 Smoldering/chronic: Q80 -Adult T-cell Leukemia/LymphomaIs there a role for allogeneic HCT in relapsed sensitive disease? # Answer % Count 1 Yes 78.95% 15 2 No 21.05% 4 Total 100% 19
73 Q81 - Adult T-cell Leukemia/LymphomaSmoldering/chronic: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapse resistant/refractory disease? # Answer % Count 1 Yes 10.00% 2 No 90.00% 18 Total 100% 20
74 Q82 -Adult T-cell Leukemia/LymphomaSmoldering/chronic: Is there a role for allogeneic HCT in relapse resistant/refractory disease? # Answer % Count 1 Yes 76.47% 13 2 No 23.53% 4 Total 100% 17
75 Q84 -Mycosis Fungoides/Sezary syndromeEarly stage (IA, IB, IIA) patch and/or plaque phase: Front-line: Is there a role for high-dose chemotherapy and autologous HCT as part of front-line therapy? # Answer % Count 1 Yes 0.00% 2 No 100.00% 24 Total 100%
76 Early stage (IA, IB, IIA) patch and/or plaque phase: Front-line:Q85 -Mycosis Fungoides/Sezary syndrome Early stage (IA, IB, IIA) patch and/or plaque phase: Front-line: Is there a role for allogeneic HCT as part of front-line therapy? # Answer % Count 1 Yes 4.17% 2 No 95.83% 23 Total 100% 24
77 Q86 -Mycosis Fungoides/Sezary syndromeEarly stage (IA, IB, IIA) patch and/or plaque phase: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed responsive disease? # Answer % Count 1 Yes 4.35% 2 No 95.65% 22 Total 100% 23
78 Early stage (IA, IB, IIA) patch and/or plaque phase:Q87 -Mycosis Fungoides/Sezary syndrome Early stage (IA, IB, IIA) patch and/or plaque phase: Is there a role for allogeneic HCT in relapsed responsive disease? # Answer % Count 1 Yes 52.17% 12 2 No 47.83% 11 Total 100% 23
79 Q88 - Mycosis Fungoides/Sezary syndromeEarly stage (IA, IB, IIA) patch and/or plaque phase: Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed-resistant disease? # Answer % Count 1 Yes 9.09% 2 No 90.91% 20 Total 100% 22
80 Early stage (IA, IB, IIA) patch and/or plaque phase:Q89 -Mycosis Fungoides/Sezary syndrome Early stage (IA, IB, IIA) patch and/or plaque phase: Is there a role for allogeneic HCT in relapsed-resistant disease? # Answer % Count 1 Yes 54.55% 12 2 No 45.45% 10 Total 100% 22
81 Q91 -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Front-line therapy: Is there a role for high-dose chemotherapy and autologous HCT as part of front-line therapy? # Answer % Count 1 Yes 13.64% 3 2 No 86.36% 19 Total 100% 22
82 Q92 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Front-line therapy: Is there a role for allogeneic HCT as part of front-line therapy? # Answer % Count 1 Yes 50.00% 11 2 No Total 100% 22
83 Q93 - -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed/responsive disease? # Answer % Count 1 Yes 20.00% 4 2 No 80.00% 16 Total 100% 20
84 Is there a role for allogeneic HCT in relapsed/responsive disease?Q94 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Is there a role for allogeneic HCT in relapsed/responsive disease? # Answer % Count 1 Yes 100.00% 22 2 No 0.00% Total 100%
85 Q95 --Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Is there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed-resistant disease? # Answer % Count 1 Yes 4.55% 2 No 95.45% 21 Total 100% 22
86 Is there a role for allogeneic HCT in relapsed-resistant disease?Q96 - -Advanced stage disease (IIB-IVB): tumor phase, Sezary syndrome, and/or nodal/extracutaneous disease Is there a role for allogeneic HCT in relapsed-resistant disease? # Answer % Count 1 Yes 85.71% 18 2 No 14.29% 3 Total 100% 21
87 Q98 -Subcutaneous panniculitis-like T cell lymphomaFront-line: Is there a role for high-dose chemotherapy and autologous HCT as part of front-line consolidation? # Answer % Count 1 Yes 31.58% 6 2 No 68.42% 13 Total 100% 19
88 Q99 -Subcutaneous panniculitis-like T cell lymphomaFront-line: Is there a role for allogeneic HCT as part of front-line consolidation? # Answer % Count 1 Yes 31.58% 6 2 No 68.42% 13 Total 100% 19
89 Q100 -Subcutaneous panniculitis-like T cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of chemosensitive relapsed disease? # Answer % Count 1 Yes 55.56% 10 2 No 44.44% 8 Total 100% 18
90 Q101 -Subcutaneous panniculitis-like T cell lymphomaIs there a role for allogeneic HCT in chemosensitive relapsed disease? # Answer % Count 1 Yes 84.21% 16 2 No 15.79% 3 Total 100% 19
91 Q102 -Subcutaneous panniculitis-like T cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of chemoresistant/refractory disease? # Answer % Count 1 Yes 5.26% 2 No 94.74% 18 Total 100% 19
92 Q103 -Subcutaneous panniculitis-like T cell lymphomaIs there a role for allogeneic HCT in chemoresistant/refractory disease? # Answer % Count 1 Yes 72.22% 13 2 No 27.78% 5 Total 100% 18
93 Q105 -Enteropathy associated T-cell lymphomaFront-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation? # Answer % Count 1 Yes 73.91% 17 2 No 26.09% 6 Total 100% 23
94 Front-line: Q106 -Enteropathy associated T-cell lymphomaIs there a role for allogeneic HCT in front-line consolidation? # Answer % Count 1 Yes 11.76% 2 No 88.24% 15 Total 100% 17
95 Q107 -Enteropathy associated T-cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed disease? # Answer % Count 1 Yes 66.67% 14 2 No 33.33% 7 Total 100% 21
96 Q108 -Enteropathy associated T-cell lymphoma Is there a role for allogeneic HCT in relapsed disease? # Answer % Count 1 Yes 94.44% 17 2 No 5.56% Total 100% 18
97 Q110 -Hepatosplenic Gamma Delta T-cell lymphomaFront-line: Is there a role for high-dose chemotherapy and autologous HCT in front-line consolidation? # Answer % Count 1 Yes 55.00% 11 2 No 45.00% 9 Total 100% 20
98 Front-line: Q111 - Hepatosplenic Gamma Delta T-cell lymphomaIs there a role for allogeneic HCT in front-line consolidation? # Answer % Count 1 Yes 93.75% 15 2 No 6.25% Total 100% 16
99 Q112 - Hepatosplenic Gamma Delta T-cell lymphomaIs there a role for high-dose chemotherapy and autologous HCT in treatment of relapsed disease? # Answer % Count 1 Yes 40.00% 8 2 No 60.00% 12 Total 100% 20
100 Q113 - Hepatosplenic Gamma Delta T-cell lymphoma Is there a role for allogeneic HCT in relapsed disease? # Answer % Count 1 Yes 100.00% 21 2 No 0.00% Total 100%
101 Q115 - When performing an autologous HCT,what is your preferred conditioning regimen # Answer % Count 1 BEAM/BEAC 95.00% 19 2 TBI-based 0.00% 3 CBV 5.00% 4 Thiotepa-based 5 Other Total 100% 20
102 Q116 - Is there a role for post-autologousmaintenance therapy in mature T/NK-cell lymphomas? # Answer % Count 1 Yes 5.00% 2 No 95.00% 19 Total 100% 20
103 Q117 - IF yes, please specify histology type and regimen?in CD30+ expressing lymphomas
104 Q118 - When performing an allogeneic HCT, what is yourpreferred regimen intensity? # Answer % Count 1 Myeloablative 21.05% 4 2 Reduced intensity/non-myeloablative 78.95% 15 Total 100% 19
105 Q119 - Which regimen, why, and is there a specific disease histologyFluMel or FluCyTBI. Reserve myeloablative for young patients with high risk disease intensity depends on co-morbidities and age of patient. Cy/TBI or Bu/Cy regimen. Adult T-cell LL- leukemia- ablative regimen preferred for eligible patients targeted busulfan/fludara Fludarabine/melphalan, Flu/Cy + ldTBI Different but for NHL Flu/Mel Flu-Bu2; moderate intensity (get some cytoreduction) but lower TRM than myeloablative many RIC regimens; avoid myeloablative in lymhomas FLU-BU (FB4), better disease control. All histologies Fludarabine plus 6.4mg/kg IV busulfan (total dose) used for nearly all T-cell lymphomas
106 Q119 - Which regimen, why, and is there a specific disease histologyNo strong preference, age related Flu-Mel, center policy, myeloablative if young patient and first SCT. No difference depending on histology Sequential conditioning Fludarabin, Busulfan, Cyclophosphamid; no specific disease histology Flu-Bu-ATG
107 Q120 - What is your preferred cell sourcewhen performing an allogeneic HCT in mature T/NK-cell lymphomas? # Answer % Count 1 PBSC 94.74% 18 2 BM 5.26% Total 100% 19